RAPH — Raphael Pharmaceutical Income Statement
0.000.00%
Last trade - 00:00- $4.35m
- $4.60m
Annual income statement for Raphael Pharmaceutical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2009 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.066 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0.012 | — | — | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 0.828 | 1.63 | 3.32 | 1.33 | 1.51 |
| Operating Profit | -0.761 | -1.63 | -3.32 | -1.33 | -1.51 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -0.761 | -1.63 | -3.36 | -1.34 | -1.52 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.761 | -1.63 | -3.36 | -1.34 | -1.52 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.761 | -1.63 | -3.36 | -1.34 | -1.52 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -0.761 | -1.63 | -3.36 | -1.34 | -1.52 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.008 | -0.145 | -0.234 | -0.08 | -0.081 |
| Dividends per Share |